Clincosm LogoSign in Get a demo

egfr gene mutation

Showing 1 - 25 of 39
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
  • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Jan 22, 2023

NSCLC, EGFR Gene Mutation, Brain Metastases Trial in Worldwide (AZD3759, Erlotinib, Gefitinib)

Completed
  • Non-small Cell Lung Cancer
  • +2 more
  • Hefei, Anhui, China
  • +57 more
Nov 18, 2022

Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

Recruiting
  • Lung Cancer, Non-small Cell
  • +4 more
  • Genomic profiles detection
  • circulating tumor DNA detection
  • Changsha, Hunan, China
    Department of Oncology, The Second Xiangya Hospital, Central Sou
Oct 25, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

Recruiting
  • Lung Cancer
  • +3 more
  • Sensus Smartwatch Application
  • +3 more
  • Charlottesville, Virginia
    University of Virginia
Aug 26, 2022

Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

Recruiting
  • Lung Adenocarcinoma Stage III
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Aug 13, 2022

Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

Recruiting
  • Lung Cancer Metastatic
  • EGFR Gene Mutation
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Non-squamous NSCLC, EGFR Gene Mutation Trial in Chengdu (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Not yet recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
  • Chengdu, Sichuan, China
  • +2 more
May 24, 2022

NSCLC Stage IV, EGFR Gene Mutation Trial in Worldwide (Osimertinib, Stereotactic Body Radiation Therapy (SBRT))

Recruiting
  • NSCLC Stage IV
  • EGFR Gene Mutation
  • Alessandria, Italy
  • +15 more
Mar 29, 2022

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • EGFR Gene Mutation
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 27, 2022

    Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

    Recruiting
    • Carcinoma, Non-Small Cell Lung
    • EGFR Gene Mutation
    • Gemcitabine platinum combined with erlotinib
    • Changsha, Hunan, China
      Hunan Province Tumor Hospital
    Feb 28, 2022

    EGFR Gene Mutation, Nonsmall Cell Lung Cancer Trial in Washington, Hackensack (Dasatinib, Osimertinib)

    Active, not recruiting
    • EGFR Gene Mutation
    • Nonsmall Cell Lung Cancer
    • Washington, District of Columbia
    • +1 more
    Jan 9, 2022

    Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

    Recruiting
    • Non-Small Cell Carcinoma of Lung, TNM Stage 4
    • +5 more
      • Aurora, Colorado
        University of Colorado, Cancer Center
      Nov 3, 2021

      NSCLC, EGFR Gene Mutation, EGF-R Positive NSCLC Trial in Jerusalem (Stereotactic surgery)

      Recruiting
      • NSCLC
      • +4 more
      • Stereotactic surgery
      • Jerusalem, Israel
        Hadassah Ein Kerem Medical Center
      Aug 30, 2021

      EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic Trial in United States (Dacomitinib, Osimertinib)

      Recruiting
      • EGFR Gene Mutation
      • +2 more
      • Basking Ridge, New Jersey
      • +7 more
      Aug 27, 2021

      EGFR Gene Mutation Trial in Korea, Republic of (YH25448)

      Active, not recruiting
      • EGFR Gene Mutation
      • Cheongju-si, Chungcheongbuk-do, Korea, Republic of
      • +15 more
      Aug 10, 2021

      Lung Tumors, EGFR Gene Mutation Trial in Hwasun (Afatinib)

      Completed
      • Lung Neoplasms
      • EGFR Gene Mutation
      • Hwasun, Jeonnam, Korea, Republic of
        Chonnam National University Hwasun Hospital
      Aug 1, 2021

      NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

      Recruiting
      • NSCLC Stage IIIB
      • +4 more
      • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
      • Carboplatin + Pemetrexed + Atezolizumab
      • Angers, France
      • +30 more
      Jun 7, 2021

      NSCLC, EGFR Gene Mutation Trial in Hangzhou, Liuzhou (D-0316 Capsule, Icotinib Hydrochloride Tablets)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • EGFR Gene Mutation
      • D-0316 Capsule
      • Icotinib Hydrochloride Tablets
      • Hangzhou, Zhejiang, China
      • +1 more
      May 10, 2021